We studied differences in the glucose metabolism, lipid pattern and apolipoprotein A and B after one month of combined hemodialysis-hemoperfusion (HD-HP) in eight regular maintenance hemodialysis (HD) patients.
After one month of HD-HP predialytic serum creatinine and phosphate were lower than during the preceding HD period; the lipidic pattern and apolipoproteins were unchanged. A single HD-HP session significantly reduced triglycerides; this does not occur during HD. Postdialytic changes of all other lipoprotein metabolism parameters are identical in the two techniques.
As regards glucose metabolism, after one month of regular HD-HP treatment glycemic curves during the intravenous glucose tolerance test (IVGTT) were perfectly matched with those in HD. However, insulin production was lower, with a reduction of the insulin resistance index. Differences did not reach statistical significance.
The Authors infer that activated charcoal, even though it achieves better blood purification in uremia, may be unable to remove specific substances which hamper some key enzyme activities of the carbohydrate and lipid metabolism.
HampersCL, SoeldnerJS, DoakPB, MerrillJP. Effect of chronic renal failure and hemodialysis on carbohydrate metabolism. J Clin Invest1966; 45:1719–31.
2.
AllegraV, MengozziG, SpulzaroP, TentiM, AmendolagineF, VasileA.Comportamento del tasso plasmatico dell'IRI e dell'HGH dopo carico di glucosio per os e per vena in pazienti uremici in terapia conservativa ed emodialitica. Atti del 3° Convegno di Nefrologia e Dialisi. Bardonecchia1983; 347–51.
3.
De FronzoRA, SmithJD. Is glucose intolerance harmful for the uremic patient?Kidney Int1985; (Suppl 17), S88–S97.
4.
De FronzoRA, AlvestrandA, SmithD, HendlerR, HendlerE, WahrenJ.Insulin resistance in uremia. J Clin Invest1981;67:563–8.
5.
BagdadeJD, PorteD, BiermanEL. Hypertriglyceridemia. A metabolic consequence of chronic renal failure. N Eng J Med1968;279:181–5.
6.
ChanMK, VargheseZ, MoorheadJF. Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int1981; 19:625–37.
7.
AllegraV, AmendolagineF, MengozziG, VasileA.Alterazioni del metabolismo glico-lipidico in pazienti emodializzati: correlazione tra le varie anomalie e loro importanza nella quantizzazione del rischio vasculare. In: TimioM, VenanziS, eds. “Cuore e Rene”.Milano: Abetre, 1987; 179–86.
8.
BagdadeJ, CasarettoA, AlbersJ.Effects of chronic uremia, hemodialysis and renal transplantation on plasma lipids and lipoproteins in man. J Lab Clin Med1976; 87:37–48.
9.
RapaportJ, AviramM, ChaimovitzC, BrookJG. Defective high-density lipoprotein composition in patients on chronic hemodialysis. A possible mechanism for accelerated atherosclerosis. N Engl J Med1978; 299:1326–9.
10.
HenningHV, BalusekE.Lipid metabolism in uremia: effect of regular hemofiltration and hemodialysis treatment. J Dial1977; 1:595–605.
11.
AllegraV, AmendolagineF, MengozziG, Insulinoresistenza e lipoproteine in soggetti emodializzati. In: RamelloA, MalcangiV, eds. Moderne acquisizioni in nefrologia e dialisi.Bologna: Monduzzi, 1985; 83–9.
12.
DzürikR, SpustovaV.Pathogenesis of metabolic alterations in renal failure. Czch Med1984; 7:191–200.
13.
McCalebML, IzzoMS, LockwoodDH. Characterization and partial purification of a factor from uremic serum that induces insulin resistance. J Clin Invest1985; 75:391–6.
14.
MuraseT, CattranDC, RubensteinB, SteinerG.Inhibition of lipoproteinlipase by uremic plasma. A possible cause of hypertriglyceridemia. Metabolism1975; 24:1279–86.
15.
GeronemusR, Von AlbertiniB, GlabnumS, KahnT, RayfieldE, BoschJP. Glucose tolerance in patients on hemodialysis, sequential ultrafiltration and dialysis and hemofiltration. Proc EDTA1979; 16:698–9.
16.
GeronemusR, BoschJB, ThorntonJ, RayfieldEJ. Studies of carbohydrate metabolism after hemodialysis and hemofiltration in uremic patients. Arch Int Med1982; 142:707–10.
17.
CivatiG, GalatoR, FranceschiniG, GuastoniC, PeregoA, MinettiL.Aspetti del metabolismo lipidico in emofiltrazione. Confronto con l'assetto lipidico dell'emodializzato. Min Nef roi1980; 27:669–74.
18.
GurlandHJ, CastroLA, SamtlebenW, FernandezJC. Combination of hemodialysis and hemoperfusion in a single unit for treatment of uremia. Clin Nephrol1979; 11:167–72.
19.
BonominiV, StefoniS, CascianiCU, Multicentre experience with combined hemodialysis/hemoperfusion in uremia. Contrib Nephrol1982; 29:133–42.
20.
StefoniS, ColiL, FeliciangeliG, BaldratiL, BonominiV.Regular hemoperfusion in regular dialysis treatment. A long-term study. Int J Artif Organs1980; 3:348–53.
21.
StefoniS, FeliciangeliG, ColiL, ScolariMP, BonominiV.Combined hemodialysis-hemoperfusion treatment reduces the time of substitutive therapy in chronic uremia. Int J Artif Organs1981; 4:186–91.
22.
CascianiCU, CarusoU, CravottoE, Lipid pattern during dialysis with cuprophan and hemodialysis hemoperfusion. Abstr. 27° Annual Meeting ASAIO, Chicago1982; 44.
23.
AllegraV, MengozziG, SpulzaroP, AmendolagineF, VasileA.Modificazioni della tolleranza glicidica, della produzione insulinica e dell'insulinoresistenza dopo trapianto renale. Min Urol Nefrol1984; 36:293–9.
24.
FriedewaldWT, LevyRI, FredricksonDS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem1972; 18:499–502.
25.
WilsonPWF, ZechLA, GreggRE, Estimation of VLDL cholesterol in hyperlipemia. Clin Chim Acta1985; 151:285–91.
26.
GurlandHJ. Hemoperfusion in the treatment of uremia. Kidney Int1985; 28 (Suppl. 17) S47–S49.
27.
WinchesterJF, AshSR. Hemoperfusion for uremia: past, present, and future. Kidney Int1985; 28 (Suppl. 17), S127–S130.
28.
WinchesterJF, RatcliffeJG, CarlyleE, KennedyAC. Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia. Kidney Int1978; 14: 74–81.
29.
ChangTMS, MigchelsenM, CoffeyJF, StarkR.Serum middle molecule levels in uremia during long term intermittent hemoperfusion with the ACAC (coated charcoal) microcapsule artificial kidney. Trans ASAIO1974; 20:364–71.
